FDA Lifts Clinical Hold on Phase 1 Study of P-PSMA-101 for mCRPC
The FDA has lifted the clinical hold on the phase 1 study of P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.
The FDA has lifted the clinical hold on the phase 1 study of P-PSMA-101 in patients with metastatic castration-resistant prostate cancer (mCRPC), according to Poseida Therapuetics, the developer of the agent.
Following this announcement, the company indicated it plans to resume the trial immediately. Of note, P-PSMA-101 is the company's first solid tumor autologous CAR-T therapeutic candidate.
The phase 1 trial of P-PSMA-101 in mCRPC was initiated in May 2020. Moving forward, Poseida has agreed to implement protocol amendments per the FDA’s guidance intended to increase patient compliance and safety that include modified inclusion and exclusion criteria and frequency of monitoring and laboratory testing.
P-PSMA-101 is designed to target prostate-specific membrane antigen (PSMA), which is expressed on mCRPC cells. The agent was developed using Poseida's proprietary piggyBac DNA Modification System, which produces product candidates with a high percentage of stem cell memory T-cells.
Reference:
Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer [news release]. San Diego. Published November 2, 2020. Accessed November 2, 2020. https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-clinical-hold-lifted-on-phase-i-autologous-car-t-study-in-prostate-cancer-301164397.html
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
